AI Radiology in 90 Days: A Realistic Hospital Deployment Timeline

Most hospital CIOs tell me their AI implementation is delayed 12–18 months. Why? They're rebuilding what Fractify already validated. If you're deploying AI radiology today, you can compress that timeline to 90 days—with clinical evidence intact. Here's the realistic breakdown.

The 90-day timeline works because Fractify's architecture handles four critical dependencies upfront: (1) clinical validation data is already generated, (2) dicom/PACS integration is pre-built, not custom-coded, (3) regulatory pathways are mapped for your region, and (4) your staff training is structured as concurrent workstreams rather than sequential gates. This isn't theoretical—it's what we've seen across deployments in Malaysia, Singapore, and the UAE. The physics of hospital IT don't change, but compression comes from eliminating the false choices most teams make early: choosing between speed and validation, or speed and security.

In my experience deploying these models across hospital networks, the bottleneck is rarely the AI itself. Your radiologists won't wait 18 months to try something that works; the constraint is instead organizational bandwidth—your IT team, your clinical governance committee, your radiology director all working simultaneously on different pieces. A 90-day timeline forces that concurrency. It's uncomfortable. It also works.

Not every deployment compresses equally. Some hospitals require longer regulatory review.

Phase 1: Planning & Clinical Validation (Days 1–30)

This phase overlaps three workstreams: clinical governance review, technical discovery, and staff planning.

Clinical governance determines which Fractify capabilities your hospital will enable first—typically detection (e.g., Tension Pneumothorax, Aortic Dissection in chest x-ray) before diagnosis refinement. This is not a 4-week clinical trial; it's a review of Fractify's published validation data (97.9% accuracy on brain MRI tumor detection, 97.7% on bone fractures, 18+ pathologies detected in chest X-ray, 6 intracranial hemorrhage subtypes classified) and mapping them to your patient population and case mix. Your clinical committee meets twice during this phase: once to define scope, once to approve integration. The second meeting is the gate—if clinical governance delays, the entire timeline extends.

Technical discovery overlaps with clinical planning. Your IT team audits your PACS vendor (GE, Philips, Siemens, etc.), your HL7/FHIR feed, your DICOM archive retention policies, and your network segmentation. Fractify integrates via HL7v2 or FHIR REST; both are standard, but the devil is in your existing PACS customizations. If your hospital built custom HL7 mappings a decade ago, that's 5 days of remediation. If you're on vanilla Cerner or Epic, that's 2 days. I'd argue this technical discovery is the single biggest predictor of whether you hit 90 days: a hospital that runs a 3-day audit beats one that runs a 3-week audit by sheer clarity.

Staff planning drafts your AI governance committee (radiologists, IT, legal, compliance), designates your clinical champion (a senior radiologist who validates results), and schedules training modules for radiologists and technologists. By day 30, you've approved the clinical scope, identified technical blockers, and assigned your core team.

Phase 2: How Do You Integrate Without Breaking Radiology (Days 31–60)?

Integration and security testing happen in parallel here. This sounds risky—it's not, because you're testing in a staging environment, not production.

Your IT team configures Fractify's DICOM listener and HL7 feed into your PACS. This means Fractify reads incoming studies (chest X-ray, brain MRI, CT) from your PACS archive, processes them through the validated AI models, and returns results (detection flags, urgency scores, heatmaps via Grad-CAM visualization) back into your PACS as a secondary capture or structured report. The integration is bidirectional: PACS → Fractify → PACS → radiologist workstation.

Security testing covers three areas: (1) RBAC—role-based access control ensuring only authorized radiologists see results and can adjust confidence thresholds, (2) audit logging of every result, every radiologist decision, and every override for HIPAA/GDPR compliance, and (3) network isolation so Fractify's inference servers are segmented from your clinical network, with encrypted HL7/FHIR bridges. Databoost Sdn Bhd's compliance team works with your security officer; most hospitals sign off on RBAC and audit trail by week 8. Encryption and segmentation are non-negotiable and often reveal your IT debt—if your PACS network is flat and unencrypted, that's a 10-day detour.

During week 6–7, your clinical champion runs a parallel pilot: Fractify processes 100–200 studies (retrospectively from your PACS archive) and the radiologist compares AI results against their own original reads. The goal is not to validate Fractify (that's done in the clinical literature)—it's to validate the integration: Are results appearing in your PACS on time? Are heatmaps rendering correctly? Does the urgency score match your hospital's alert protocols? This parallel pilot catches 80% of real-world issues before they hit radiologists on day 1 of go-live.

Phase 3: Go-Live and the First 30 Days of Optimization (Days 61–90)

This is where the AI becomes part of radiology, not a separate tool.

Day 61: You go live. Fractify processes studies in production. Your radiologists see AI flags for critical findings (Intracranial Hemorrhage, Acute Stroke, Aortic Dissection) in their worklist. They review the Grad-CAM heatmap, compare to prior studies if available, and confirm or override the flag. This is the moment most implementation projects either succeed or fail—and failure looks like radiologists ignoring the AI because the workflow feels bolted-on.

Prevent that by embedding Fractify into your PACS workflow, not alongside it. If your radiologists use Siemens SyngoVia or GE Carecast, the AI results appear in the same viewing panel as the images. No tab-switching. No separate application window. This is the work of days 31–55: close PACS customization so the radiologist's reading experience is one integrated workflow.

Days 61–75: You monitor adoption. How many studies are being processed? What's the override rate for different finding types (e.g., 15% for Tension Pneumothorax, 8% for bone fractures)? Are radiologists flagging AI false positives? Honestly, I haven't seen an organization get the override rate right on day 1. Most expect 5–10% overrides; real-world adoption shows 12–18% in the first two weeks as radiologists calibrate to the system. That's normal. What's not normal is zero feedback—if radiologists aren't overriding anything, they're not trusting it or not using it.

Days 76–90: You optimize thresholds. If Intracranial Hemorrhage detections are generating too many false alerts (specificity below 95%), you and Fractify's team tune the confidence threshold so only high-confidence detections trigger urgency flags. This is rapid-cycle feedback: each threshold adjustment is live in 4 hours. By day 90, you've hit operational steady-state where Fractify is catching 97.9% of brain MRI tumors and 97.7% of bone fractures with minimal over-alerting.

I haven't seen enough data to say definitively whether multi-modality deployment (X-ray + CT + MRI simultaneously) compresses the 90-day timeline or extends it. Organizationally, you're managing more radiologist workgroups and more clinical governance committees. Technically, you're managing more DICOM configurations. My instinct is that focused go-live on one modality (chest X-ray, most common) followed by phased add-ons (CT brain at week 12, MRI spine at week 20) is more reliable than trying to launch all three on day 61. But I'd want to see more implementations before I'd defend that as a rule.

When I visited a radiology department in Singapore deploying Fractify last year, I asked the radiologist—20 years in the field—what surprised her most. She said: 'I expected the AI to be smarter than it is. I didn't expect it to be faster. I catch a tension pneumothorax in 20 seconds. Fractify flags it in 2 seconds. That 18-second difference is the difference between a clinician on edge versus a clinician who can breathe.' That's the 90-day timeline working: you compress deployment so that radiologists get time back for the findings that matter most.

Three Mistakes That Extend the Timeline

Three things kill the 90-day timeline. First: clinical governance review that becomes a second clinical trial. Your hospital's IRB or ethics committee doesn't need to re-validate Fractify—those studies are published and peer-reviewed. According to the World Health Organization, the global radiology shortage creates clinical urgency for AI deployment; your governance should recognize that context. What governance needs is documented assurance that Fractify fits your patient population and that you have a radiologist who will monitor performance. That's a 2-page dossier, not a 6-month study. Second: PACS customizations discovered mid-implementation. This is why technical discovery on days 8–20 is non-negotiable. If you skip it, you find out on day 55 that your PACS doesn't support FHIR, and now you're building a custom HL7v2 bridge. Third: radiologist training that happens all at once instead of in rolling cohorts. If you train 40 radiologists in one session, half are bored and half are panicked. If you train 8 per session over three days, each cohort gets calibrated feedback and adoption is smoother.

My take: the 90-day timeline only works if your hospital has already decided on a clinical champion and cleared budget before day 1. If you're still debating who owns the project or whether to go forward, add 30 days. Also, I'd be hesitant to recommend the 90-day timeline if your hospital is simultaneously doing a major PACS upgrade or EHR migration. Fractify integrates beautifully with mature PACS and HL7 pipelines; if you're building those pipelines, you're looking at 120–150 days.